Alliance Pharma PLC Annual Report and Notice of AGM (3729W)
April 16 2019 - 6:05AM
UK Regulatory
TIDMAPH
RNS Number : 3729W
Alliance Pharma PLC
16 April 2019
16 April 2019
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Annual Report & Accounts and Notice of AGM
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that the following documents are now available on
the Company's website, www.alliancepharmaceuticals.com:
-- The Annual Report & Accounts for the year ended 31 December 2018
-- The Notice of the 2019 Annual General Meeting ("AGM"), which
will be held at 10.00am on 23 May 2019 at the offices of Buchanan,
107 Cheapside, London EC2V 6DN
Printed copies of all the documents have been posted to those
shareholders who have opted out of receiving electronic
communications from the Company.
Printed copies of the documents are also available by contacting
Buchanan by email at alliancepharma@buchanan.uk.com or by
telephoning Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
Tejas Padalkar
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with affiliate offices in Europe,
the Far East and the US and wide international reach through an
extensive network of distributors, generating sales in more than
100 countries.
We currently own or license the rights to more than 90
pharmaceutical and consumer healthcare products, which are managed
on a portfolio basis according to their growth potential.
Promotional investment is focussed on a small number of brands with
significant international or multi-territory reach. The remainder
of the portfolio comprises products which are sold in a limited
number of local markets and require little or no promotional
investment.
Our tried and tested 'Buy and Build' strategy, allows us to
benefit both from organic growth opportunities and from enhancing
our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCIFMMTMBABBLL
(END) Dow Jones Newswires
April 16, 2019 07:05 ET (11:05 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024